Skip to main content

Dbv Technologies ADR(DBVT-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results

Globe Newswire - Mon May 2, 2022

Montrouge, France, May 2, 2022

DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results

DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced business updates concerning the regulatory status for its lead product candidate, Viaskin Peanut. The Company also reported financial results for the first quarter of 2022. The quarterly financial statements were approved by the Board of Directors on April 29, 2022.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe